Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Parkinsonism & related disorders - 1 Nov 2012

Yahalom Gilad, Kaplan Natalie, Vituri Aya, Cohen Oren S, Inzelberg Rivka, Kozlova Evgenia, Korczyn Amos D, Rosset Saharon, Friedman Eitan, Hassin-Baer Sharon

Abstract excerpt

BACKGROUND: While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy. OBJECTIVE: To assess the impact of the LRRK2 Gly2019Ser (G2019S) carrier status on the time to the onset of levodopa-induced dyskinesias (LID)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dyskinesia, Drug-Induced
Share to Glycine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Israel

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Levodopa

Share to Longitudinal Studies

Share to Serine

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 22703868
DOI: 10.1016/j.parkreldis.2012.05.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.PMID 22703868Read ↗

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.Semantic proximity Read ↗

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.Semantic proximity Read ↗

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.Semantic proximity Read ↗

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s diseaseSemantic proximity Read ↗

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.Semantic proximity Read ↗

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.Semantic proximity Read ↗

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.Semantic proximity Read ↗

G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.Semantic proximity Read ↗

The age at onset of LRRK2 p.Gly2019Ser Parkinson’s disease across ancestries and countries of originSemantic proximity Read ↗

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Semantic proximity Read ↗

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.